Literature DB >> 23938771

Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.

François Dalençon1.   

Abstract

The Session 9 of the Modern Vaccine Adjuvant/Formulation meeting pointed out the permanent need for vaccine improvement and for adjuvant development. Indeed, the increasing use of recombinant subunit vaccines for both parenteral and mucosal vaccination necessitates the development of improved adjuvants. This session dealt with strategies for the development of new vaccine adjuvants with respect to the availability of new molecules targeting specifically the receptors of the systemic or mucosal immune system.

Keywords:  T-cell response; adjuvants; formulation; mucosal immunity

Mesh:

Substances:

Year:  2013        PMID: 23938771      PMCID: PMC3906371          DOI: 10.4161/hv.26074

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  18 in total

1.  Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects.

Authors:  Tazio Storni; Christiane Ruedl; Katrin Schwarz; Reto A Schwendener; Wolfgang A Renner; Martin F Bachmann
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

Review 2.  Assessment of mucosal immunity to HIV-1.

Authors:  Vicky Jespers; Ali M Harandi; Jorma Hinkula; Donata Medaglini; Roger Le Grand; Christiane Stahl-Hennig; Willy Bogers; Raphaelle El Habib; Frank Wegmann; Carol Fraser; Martin Cranage; Robin J Shattock; Anna-Lena Spetz
Journal:  Expert Rev Vaccines       Date:  2010-04       Impact factor: 5.217

3.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines.

Authors:  Sai T Reddy; André J van der Vlies; Eleonora Simeoni; Veronique Angeli; Gwendalyn J Randolph; Conlin P O'Neil; Leslie K Lee; Melody A Swartz; Jeffrey A Hubbell
Journal:  Nat Biotechnol       Date:  2007-09-16       Impact factor: 54.908

4.  Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation.

Authors:  Susanne A Keller; Katrin Schwarz; Vania Manolova; Caroline E von Allmen; Matthias G Kinzler; Monika Bauer; Simone Muntwiler; Philippe Saudan; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2010-01       Impact factor: 5.532

Review 5.  Topical immunization strategies.

Authors:  C Czerkinsky; J Holmgren
Journal:  Mucosal Immunol       Date:  2010-09-22       Impact factor: 7.313

Review 6.  The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development.

Authors:  Ravendra Garg; Pratima Shrivastava; Sylvia van Drunen Littel-van den Hurk
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

7.  The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues.

Authors:  Anna M Eriksson; Karin M Schön; Nils Y Lycke
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

8.  NKT cell responses to glycolipid activation.

Authors:  Josianne Nitcheu Tefit; Gwyn Davies; Vincent Serra
Journal:  Methods Mol Biol       Date:  2010

9.  C3d of complement as a molecular adjuvant: bridging innate and acquired immunity.

Authors:  P W Dempsey; M E Allison; S Akkaraju; C C Goodnow; D T Fearon
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

10.  Adjuvants of immunity: harnessing innate immunity to promote adaptive immunity.

Authors:  Albert Bendelac; Ruslan Medzhitov
Journal:  J Exp Med       Date:  2002-03-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.